A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Bipolar Depression
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Esketamine (Primary)
- Indications Bipolar depression
- Focus Therapeutic Use
- Sponsors Celon Pharma
- 04 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Apr 2020.
- 04 Nov 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2020.
- 25 Oct 2018 New trial record